Researchers introduced a high‑throughput chemistry-plus‑cellular assay pipeline that diversifies ligands to discover molecular glues capable of inducing target degradation. The team focused on ENL, a chromatin protein driving certain leukemias, and identified a compound that selectively triggers ENL degradation in cells, suppressing ENL‑dependent leukemia growth. Results were published in Nature Chemical Biology. Molecular glues reprogram endogenous degradation machinery to eliminate disease proteins; the study shows a practical path from ligand diversification to functional degraders in living cells. For targeted‑therapy developers, the method reduces the gap between binder discovery and in‑cell efficacy testing and may accelerate molecular‑glue campaigns across oncology targets.